AERIE PHARMACEUTICALS INC's ticker is AERI and the CUSIP is 00771V108. A total of 157 filers reported holding AERIE PHARMACEUTICALS INC in Q3 2022. The put-call ratio across all filers is 0.60 and the average weighting 0.3%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2022 | $9,053,000 | +13.9% | 598,325 | -43.5% | 0.05% | +24.3% |
Q2 2022 | $7,947,000 | +71.2% | 1,059,565 | +107.7% | 0.04% | +146.7% |
Q1 2022 | $4,643,000 | +25.9% | 510,208 | -2.9% | 0.02% | +66.7% |
Q4 2021 | $3,688,000 | -70.2% | 525,422 | -51.5% | 0.01% | -69.0% |
Q3 2021 | $12,360,000 | -27.6% | 1,084,188 | +1.6% | 0.03% | -27.5% |
Q2 2021 | $17,077,000 | -2.8% | 1,066,622 | +8.5% | 0.04% | -13.0% |
Q1 2021 | $17,573,000 | +38.5% | 983,365 | +4.7% | 0.05% | +39.4% |
Q4 2020 | $12,685,000 | +16.9% | 938,927 | +1.8% | 0.03% | +3.1% |
Q3 2020 | $10,852,000 | -57.2% | 922,045 | -46.3% | 0.03% | -61.4% |
Q2 2020 | $25,339,000 | -32.8% | 1,716,713 | -38.6% | 0.08% | 0.0% |
Q1 2020 | $37,718,000 | +45.7% | 2,793,964 | +160.9% | 0.08% | -12.6% |
Q4 2019 | $25,881,000 | +173.8% | 1,070,792 | +117.8% | 0.10% | +156.8% |
Q3 2019 | $9,451,000 | -19.3% | 491,706 | +24.1% | 0.04% | -17.8% |
Q2 2019 | $11,711,000 | -10.6% | 396,317 | +43.8% | 0.04% | -13.5% |
Q1 2019 | $13,095,000 | +145.0% | 275,689 | +86.2% | 0.05% | +108.0% |
Q4 2018 | $5,344,000 | -48.5% | 148,025 | -12.1% | 0.02% | -35.9% |
Q3 2018 | $10,369,000 | -16.4% | 168,471 | -8.2% | 0.04% | -25.0% |
Q2 2018 | $12,398,000 | -29.7% | 183,531 | -43.6% | 0.05% | -36.6% |
Q1 2018 | $17,640,000 | -13.2% | 325,156 | -4.3% | 0.08% | -10.9% |
Q4 2017 | $20,312,000 | +18.6% | 339,943 | -3.5% | 0.09% | +15.0% |
Q3 2017 | $17,122,000 | -8.8% | 352,306 | -1.4% | 0.08% | -11.1% |
Q2 2017 | $18,772,000 | +12.6% | 357,214 | -2.8% | 0.09% | +8.4% |
Q1 2017 | $16,673,000 | +76.9% | 367,657 | +47.6% | 0.08% | +62.7% |
Q4 2016 | $9,427,000 | +36.9% | 249,063 | +36.5% | 0.05% | +45.7% |
Q3 2016 | $6,884,000 | +386.5% | 182,414 | +126.9% | 0.04% | +400.0% |
Q2 2016 | $1,415,000 | -47.1% | 80,400 | -46.7% | 0.01% | -53.3% |
Q3 2015 | $2,677,000 | -22.2% | 150,894 | -22.6% | 0.02% | 0.0% |
Q2 2015 | $3,442,000 | -74.6% | 195,035 | -54.9% | 0.02% | -75.4% |
Q1 2015 | $13,560,000 | +316.5% | 432,689 | +287.9% | 0.06% | +281.2% |
Q4 2014 | $3,256,000 | – | 111,548 | – | 0.02% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
JACOB ASSET MANAGEMENT OF NEW YORK LLC | 246,563 | $2,244,000 | 1.36% |
LEVIN CAPITAL STRATEGIES, L.P. | 1,435,876 | $13,066,000 | 1.26% |
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 4,695,020 | $42,725,000 | 0.96% |
DCF Advisers, LLC | 189,565 | $1,725,000 | 0.76% |
DAFNA Capital Management LLC | 289,040 | $2,630,000 | 0.68% |
RICE HALL JAMES & ASSOCIATES, LLC | 1,678,609 | $15,275,000 | 0.61% |
Rhenman & Partners Asset Management AB | 589,200 | $5,362,000 | 0.53% |
PFM Health Sciences, LP | 1,088,566 | $9,906,000 | 0.37% |
NEXPOINT ASSET MANAGEMENT, L.P. | 309,778 | $2,819,000 | 0.36% |
Granahan Investment Management | 1,588,944 | $14,459,000 | 0.36% |